CureLab Veterinary Addresses a $207 billion Global Pet Cancer Market Elenavet™, the company’s flagship drug, has successfully cured 10 out of 11 dogs with breast cancer; This is an equity crowdfunding opportunity for an early equity investment where one can own a part of a promising biotechnology company
BostonAnd January 18, 2023 /PRNewswire/ — CureLab Veterinary, an animal health biotech startup, has launched its crowdfunding campaign via Netcapital, a leading investment crowdfunding platform. CureLab Veterinary’s flagship product, Elenavet™ (a super-coiled circular DNA called a plasmid), has successfully cured 10 out of 11 dogs with breast cancer.
After a recent angel investment of $2.5 millionCureLab Veterinary is targeting a large market opportunity with its treatments. There are 85 million dogs and 103 million cats in the world Europe. to me United States of America, these figures are 96 and 90 million, respectively. 43% of dogs and 32% of cats over the age of 10 suffer from cancer, and many pet parents willingly pay at least 2000 dollars For a course of cancer treatment to help their beloved pet.
“Following the success of our early clinical trials, we are eager to begin the approval process with the USDA and Production in United State To help relieve the pain and suffering of pets.” Robert Devlin, DVM, MBA, from CureLab Veterinary. “Studies have shown that when pets have cancer, the health of their owners is also at risk. Pets are essential members of the family for most American families, and CureLab veterinary company wants to help save their lives. We look forward to a larger pet-loving community to invest in for our company.” $100 dollarsInvestors can make a massive positive social impact on pets and participate in the opportunity for financial gain.”
in veterinary clinics abroad United StateElenavet has shown encouraging initial results for both dogs and cats with various types of cancer. Whether prescribed alone or in combination with additional chemotherapy agents, Elenavet, once approved, could capture and expand a significant share of the cancer treatment market.
As a secondary market after cancer, veterinary company CureLab plans to treat diseases of aging in dogs, cats, and horses. The company holds a comprehensive patent portfolio in more than 20 countries for both cancer and chronic inflammatory diseases. Osteoarthritis, for example, debilitates 80% of elderly dogs and 90% of cats.
CureLab veterinary has already established a constructive dialogue with regulators in United State (USDA-CVB) and the European Union (CVM). The company wishes to obtain a conditional license in the United States within 36 months after the conclusion of the investment round. A conditional license gives the company the right to sell at a profit. An alternative business strategy might be licensing the product to a pharmaceutical company.
Founder of veterinary company CureLab, Dr. Alexander Schneider. “This gatekeeper is collectively known as Wall Street – the venture capitalists, the insurance companies, or any other form of corporate ‘wisdom’ that stands between us and the innovators and the people we commit to helping. We are leveling the playing field with crowdfunding Reg CF Show. Anyone—from a student to a Fortune 500 CEO—can become a part of the success of CureLab Veterinary. To me, that’s the highest form of economic democracy and that’s why we chose crowdfunding over other types of fundraising.”
CureLab Veterinary’s crowdfunding campaign is now live. Anyone can invest through the Netcapital platform.
About CureLab Veterinary
Today, the four-legged members of our family live longer than ever before. Unfortunately, with such a longer lifespan, our furry friends now suffer from many of the same cancers and diseases due to the chronic infections their parents suffered from. CureLab Veterinary, a sister company of CureLab Oncology, is dedicated to providing advanced therapies for the treatment of cancer and inflammatory diseases to support better health and longevity in pets. To learn more, visit curelabveterinary.com.
Tim CoxZingPR [email protected]
Source Cure Lab veterinary